MARKET

RNAC

RNAC

Cartesian
NASDAQ
23.04
+0.24
+1.05%
Closed 16:00 06/24 EDT
OPEN
22.36
PREV CLOSE
22.80
HIGH
26.36
LOW
22.36
VOLUME
103.13K
TURNOVER
0
52 WEEK HIGH
42.60
52 WEEK LOW
11.67
MARKET CAP
410.02M
P/E (TTM)
-0.4798
1D
5D
1M
3M
1Y
5Y
Cartesian Therapeutics Price Target Maintained With a $50.00/Share by Oppenheimer
Dow Jones · 15h ago
Oppenheimer Reiterates Outperform on Cartesian Therapeutics, Maintains $50 Price Target
Benzinga · 15h ago
Weekly Report: what happened at RNAC last week (0617-0621)?
Weekly Report · 22h ago
Analysts’ Top Healthcare Picks: Intra-Cellular Therapies (ITCI), Gilead Sciences (GILD)
Intra-Cellular Therapies (ITCI) and Gilead Sciences (GILD) have been recommended by 3 analysts with bullish sentiments. Intra- cellulartherapies has an average price target of $94.69, while gilead sciences has a target price of $90.
TipRanks · 6d ago
Cartesian Therapeutics’ Strategic Governance and Incentive Enhancements
TipRanks · 06/17 15:15
Cartesian: Current report
Press release · 06/17 12:15
Cartesian Therapeutics Price Target Maintained With a $54.00/Share by HC Wainwright & Co.
Dow Jones · 06/17 11:05
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Encompass Health (EHC) and Sarepta Therapeutics (SRPT)
TipRanks · 06/17 11:01
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.